PI3K Oct 14, 2021 Rhizen Pharmaceuticals Begins Phase II Trial of PI3K Inhibitor in Breast Cancer Jul 30, 2021 Mount Sinai Seeking Pharma Partner to Advance Promising AKT Degrader Premium Jul 6, 2021 Novartis, Kura Oncology Partner on Phase I/II Head and Neck Cancer Study of Piqray, Tipifarnib Apr 9, 2021 Celcuity Licenses PI3K/mTOR Inhibitor from Pfizer, Enters $25M Debt Financing Agreement Dec 15, 2020 Roche Nabs CE Mark for PIK3CA Test for Breast Cancer Nov 12, 2020 Denovo Biopharma Completes Enrollment for Trial Evaluating Enzastaurin in DGM1-Positive DLBCL Sep 25, 2020 Relay Therapeutics Uses Protein Motion Simulation to Develop Highly Selective Precision Cancer Drugs Premium Sep 20, 2020 Advanced Breast Cancer Patients Benefit From Targeted, Conventional Therapy Combo, ESMO Studies Show Premium Sep 4, 2020 Mutations in FOXA1 Gene Can Affect Breast Cancer Patients' Response to Therapy Aug 4, 2020 BostonGene Partners With Dana-Farber's Weinstock Lab on T-Cell Lymphoma Biomarker Research Jul 7, 2020 Menarini to Launch Trial Evaluating PI3K Inhibitor MEN1611 in Metastatic Colorectal Cancer Jun 1, 2020 Novartis' Piqray Effective in Breast Cancer Subset; Bayer's Aliqopa Gives Limited Signals in NCI-MATCH Apr 1, 2020 Mutations in PTEN, ESR1 Promote Piqray Resistance in HR-Positive Breast Cancer, Study Finds Feb 26, 2020 iOnctura Doses First Patient in Phase I Study of Novel PI3K Inhibitor for Solid Tumors Nov 19, 2019 Double Mutations in PIK3CA Gene Increase Patient Sensitivity to Targeted Therapies, Study Finds Premium May 24, 2019 FDA Approves Novartis' Piqray for PIK3CA-Mutated Advanced Breast Cancer Dec 7, 2018 Novartis Drug Shows Promise in PIK3CA Mutated Breast Cancer, Potential Utility of ctDNA Testing Premium Jun 3, 2018 ASCO Study Shows Modest Efficacy of PI3 Kinase Inhibitor in Molecularly Defined Breast Cancer Premium Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
